Aldosterone synthase (CYP11B2) is the key enzyme responsible for the final steps in aldosterone production, a steroid hormone that plays a critical role in the regulation of electrolyte balance and ...
Lorundrostat, a novel therapy which blocks the production of aldosterone from the adrenal glands, demonstrated clinically meaningful and sustained reductions in blood pressure in 1,083 patients with ...
Credit: Getty Images Investigators report promising results from a phase 2 trial of an investigational aldosterone synthase inhibitor. Combining the aldosterone synthase inhibitor with empagliflozin ...
Please provide your email address to receive an email when new articles are posted on . BI 690517 dose-dependently reduced urine albumin-to-creatine ratio, showing a potential albuminuria reduction.
Novel combinations and targeted pathway inhibitors may improve adherence and blood pressure control in patients with ...
Current treatment options for primary aldosteronism are limited to surgery or mineralocorticoid receptor antagonists when surgery isn't an option. In a phase IIa trial, baxdrostat resolved or reduced ...
In a phase 2 trial, an investigational drug that inhibits aldosterone synthase significantly lowered albuminuria in patients with or without type 2 diabetes. PHILADELPHIA—A novel selective aldosterone ...
Despite the availability of effective antihypertensive therapies, global blood pressure control rates remain unacceptably low. Contributing factors, such as low treatment adherence, therapeutic ...
– Lorundrostat, a highly selective aldosterone synthase inhibitor, demonstrated robust, double-digit reduction in systolic blood pressure (BP) with a well-tolerated profile – – Enhanced reduction in ...
Once-daily treatment with the selective aldosterone synthase inhibitor lorundrostat (Mineralys Therapeutics) safely and significantly reduced blood pressure in adults with uncontrolled hypertension in ...
A highly selective aldosterone synthase inhibitor, lorundrostat, showed promise for blood pressure reduction in a double-blind randomized phase IIb trial. Participants with uncontrolled and otherwise ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results